Relationship of neuroendocrine differentiation to biological behavior of prostate cancer

National Medical Journal of China

Volumn 89, Issue 7, 2009, Pages 472-475

  Wu, Xiu Ling ^a   Huang, Ka Te ^a   Chen, Wei ^a   Chen, Lin ^a   Dong, Lei ^a   Yu, Zhi Xian ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Neuroendocrine tumors; Prognosis; Prostatic neoplasms

Indexed keywords

ANTIANDROGEN; CHROMOGRANIN A; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ANTIANDROGEN THERAPY; ARTICLE; BONE SCINTISCANNING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PROSTATE CANCER; PROTEIN EXPRESSION; THORAX RADIOGRAPHY; TRANSURETHRAL RESECTION; TUMOR DIFFERENTIATION; AGED; BLOOD; CYTOLOGY; FOLLOW UP; METABOLISM; NEUROSECRETORY CELL; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR;

AGED; ANDROGEN ANTAGONISTS; CHROMOGRANIN A; FOLLOW-UP STUDIES; HUMANS; MALE; NEUROENDOCRINE CELLS; NEUROENDOCRINE TUMORS; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 77954925963     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2009.07.010     Document Type: Article

References (12)

1. Hirano D, Okada Y, Minei S, et al. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol, 2004, 45:586-592. (Pubitemid 38481685)
2. Nelson EC, Cambio AJ, Yang JC ,et al. Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer and Prostatic Dis,2007, 10:6-14.
3. Grobholz R, Griebe M, Sauer CG, et al. Influence of neuroendocrine tumour on proliferation in prostate cancer. Human Pathol , 2005,36: 562-570. (Pubitemid 40776010)
4. Ferrero-Poüs M, Hersant AM, Pecking A, et al. Serum chromogranin-A in advanced prostate cancer. BJU Int, 2001 , 88: 790-796. (Pubitemid 33755128)
5. Berruti A, Dogliotti L, Mosca A , et al. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Ann Oncol,2001,12 Suppl 2:153-157.
6. Kadmon D, Thompson TC, Lynch GK, et al. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol, 1991,146:358-361.
7. May M, Siegsmund M, Hammermann F, et al. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy. Scand J Urol Nephrol, 2007,41: 375-381. (Pubitemid 350034696)
8. Berruti A , Mosca A, Porpiglia F, et al. Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease. J Urol , 2007, 178: 838-843.
9. Deftos LJ, Nakada S, Burton DW, et al. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology, 1996, 48:58-62. (Pubitemid 26255959)
10. Kronen LM, Bogdanowicz FA , Seldenrijk CA, et al. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol , 1997,158: 171-174.
11. Lee LF, Louie MC, Desai SJ, et al. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene, 2004,23:2197-2205.